Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 25;14(23):5824.
doi: 10.3390/cancers14235824.

Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis

Fabio Carboni  1 , Mario Valle  1 , Marco Vaira  2 , Paolo Sammartino  3 , Orietta Federici  1 , Manuela Robella  2 , Marcello Deraco  4 , Massimo Framarini  5 , Antonio Macrì  6 , Cinzia Sassaroli  7 , Piero Vincenzo Lippolis  8 , Andrea Di Giorgio  9 , Daniele Biacchi  3 , Lorena Martin-Roman  4 , Isabella Sperduti  10 , Dario Baratti  4
Affiliations

Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis

Fabio Carboni et al. Cancers (Basel). .

Abstract

Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy may significantly improve survival for selected patients with peritoneal surface malignancies, but it has always been criticized due to the high incidence of postoperative morbidity and mortality.

Methods: Data were collected from nine Italian centers with peritoneal surface malignancies expertise within a collaborative group of the Italian Society of Surgical Oncology. Complications and mortality rates were recorded, and multivariate Cox analysis was used to identify risk factors.

Results: The study included 2576 patients. The procedure was mostly performed for ovarian (27.4%) and colon cancer (22.4%). The median peritoneal cancer index was 13. Overall postoperative morbidity and mortality rates were 34% and 1.6%. A total of 232 (9%) patients required surgical reoperation. Multivariate regression logistic analysis identified the type of perfusion (p ≤ 0.0001), body mass index (p ≤ 0.0001), number of resections (p ≤ 0.0001) and colorectal resections (p ≤ 0.0001) as the strongest predictors of complications, whereas the number of resections (p ≤ 0.0001) and age (p = 0.01) were the strongest predictors of mortality.

Conclusions: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a valuable option of treatment for selected patients with peritoneal carcinomatosis providing low postoperative morbidity and mortality rates, if performed in high-volume specialized centers.

Keywords: HIPEC; cytoreductive surgery; morbidity; mortality; peritoneal surface malignancies; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Association between surgical complications and histology.
Figure 2
Figure 2
Association between grading of complications and histology.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nichiforkin A., Gushchin V., King M.C., Baron E., Nieroda C., Sittig M., Sardi A. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience. J. Surg. Oncol. 2021;123:1030–1044. doi: 10.1002/jso.26371. - DOI - PubMed
    1. Leigh N.L., Solomon D., Feingold D., Magge D.R., Golas B.J., Sarpel U., Labow D.M. Improved Survival with Experience: A 10-Year Learning Curve in Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery. Ann. Surg. Oncol. 2020;27:222–231. doi: 10.1245/s10434-019-07518-1. - DOI - PubMed
    1. Carboni F., Federici O., Zazza S., Corona F., Massimi F., Sperduti I., Valle M. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of non-primary origin. Langenbecks Arch. Surg. 2021;406:2817–2825. doi: 10.1007/s00423-021-02354-y. - DOI - PubMed
    1. Passot G., Vaudoyer D., Villeneuve L., Kepenekian V., Beaujard A.-C., Bakrin N., Cotte E., Gilly F.-N., Glehen O. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1.125 procedures. J. Surg. Oncol. 2016;113:796–803. doi: 10.1002/jso.24248. - DOI - PubMed
    1. Mielko J., Rawicz-Pruszyński K., Sędłak K., Gęca K., Kwietniewska M., Polkowski W.P. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Learning Curve Based on Surgical and Oncological Outcomes. Cancers. 2020;23:2387. doi: 10.3390/cancers12092387. - DOI - PMC - PubMed

LinkOut - more resources